CLINICAL TRIALS PROFILE FOR DAROLUTAMIDE
✉ Email this page to a colleague
All Clinical Trials for darolutamide
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02200614 ↗ | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer | Completed | Orion Corporation, Orion Pharma | Phase 3 | 2014-09-12 | The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer. |
NCT02200614 ↗ | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer | Completed | Bayer | Phase 3 | 2014-09-12 | The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer. |
NCT02799602 ↗ | ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | Orion Corporation, Orion Pharma | Phase 3 | 2016-11-30 | The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. |
NCT02799602 ↗ | ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | Active, not recruiting | Bayer | Phase 3 | 2016-11-30 | The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for darolutamide
Condition Name
Clinical Trial Locations for darolutamide
Trials by Country
Clinical Trial Progress for darolutamide
Clinical Trial Phase
Clinical Trial Sponsors for darolutamide
Sponsor Name